Pfizer-backed Priovant wins FDA priority review for lead asset
Source: SeekingAlpha
2026-03-03 07:24:49 ET
More on Pfizer, Roivant Sciences
- Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Pfizer: A Risky 6.3% Yield For Income-Oriented Investors
- Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
- FDA reportedly eyeing staff bonuses to accelerate drug reviews
- CDC advisory meeting in March to focus on COVID-19 vaccine injuries, long COVID
Read the full article on Seeking Alpha
For further details see:
Pfizer-backed Priovant wins FDA priority review for lead asset
Roivant Sciences Ltd.
NASDAQ: ROIV
ROIV Trading
-0.05% G/L:
$29.965 Last:
1,359,287 Volume:
$29.49 Open:
ROIV Latest News
March 04, 2026 11:42:41 pm
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide
March 03, 2026 04:15:00 pm
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
March 03, 2026 04:15:00 pm
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
ROIV Stock Data
$19,574,426,097
449,460,314
0.77%
170
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
